First real success for anti-HIV gel: a new start for HIV microbicides? (Q42785516)

7 November 2017

0 references

First real success for anti-HIV gel: a new start for HIV microbicides? (English)

1 reference

7 November 2017

Kevin K Ariën

1

1 reference

PubMed ID

21133683

7 November 2017

Guido Vanham

series ordinal

2

1 reference

7 November 2017

1 November 2010

1 reference

7 November 2017

3

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

7 November 2017

5

1 reference

7 November 2017

11

1 reference

7 November 2017

1621-1623

1 reference

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

7 November 2017

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

SAVVY® (C31G) Gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

HIV trial doomed by design, say critics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.129

21 January 2018

Identifiers

DOI

10.2217/FMB.10.129

1 reference

7 November 2017

1 reference

PubMed ID

21133683